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Summary Telomerase is a specialized ribonucleoprotein polymerase that directs the synthesis of telomerase repeats at chromosome ends.
Accumulating evidence has indicated that telomerase is stringently repressed in normal human somatic tissues but reactivated in cancers and
immortal cells, suggesting that activation of telomerase activity plays a role in carcinogenesis and immortalization. In this work, the status of
telomerase activity during the development of human thyroid cancer was determined using telomeric repeat amplification protocol (TRAP) in
14 nodular hyperplasia, 14 adenomas, 23 papillary carcinomas and 11 follicular carcinomas. Positive telomerase activity was detected in 2 of
14 nodular hyperplasias (14%), 4 of 14 adenomas (29%), 12 of 23 papillary carcinomas (52%) and 10 of 11 follicular carcinomas (91%). The
cancers that are negative for telomerase activity are mostly in early stage (stage or 11). These results suggest that telomerase reactivation
plays a role during the development of thyroid cancer.
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Normal human somatic cells have a limited proliferative capacity
(Hayflick, 1965). Circumstantial evidence suggests that acquisi-
tion of extended proliferative capacity, and even of immortality,
may occur during the development of tumours (Stamps et al,
1992). Telomere length and telomerase activity have recently been
implicated in the control of the proliferative capacity of normal
and malignant cells (Harley et al, 1994). The telomeres of human
chromosomes consist of hundreds to thousands of tandem repeats
ofthe sequence TTAGGG that are specifically extended by telom-
erase, a specialized ribonucleoprotein polymerase that synthesizes
telomeric DNA onto chromosomal ends using a segment of its
integral RNA component as a template (Blackburn, 1992). Normal
human somatic cells express low or undetectable telomerase
activity and progressively lose their telomeric sequences with
replicative senescence or with ageing (Harley, 1991; Allosopp
et al, 1992; Vaziri et al, 1993). In contrast, most immortal cells
contain telomerase activity and show no net loss of telomere
sequence with cell division (Counter et al, 1992; 1994). Therefore,
the telomerase activity appears to be stringently repressed in
normal human somatic cells but reactivated in immortal cells,
suggesting that the activation of telomerase expression may
participate in cellular immortality.
Although it is not clear how shortened telomeres may contribute
to cellular senescence, the association of telomerase activation
with immortalization in vitro raised the possibility that the
immortal cells in tumours may be derived by telomerase reactiva-
tion. Telomerase activity was first demonstrated in metastatic cells
from human ovarian carcinomas (Counter et al, 1994) and malig-
nant human haematopoietic cells (Nilsson et al, 1994). The
development of a polymerase chain reaction (PCR)-based assay
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for detecting telomerase activity, termed TRAP (Kim et al, 1994),
increased the sensitivity of detection and allowed investigators to
examine telomerase activity in a large number oftumour biopsies.
A high percentage of telomerase activity was detected in primary
tumour specimens from malignancies of diverse tissue origins,
less frequently in premalignant and benign proliferative tissues,
and rarely or none in normal somatic tissues (Shay and Bacchetti,
1997). Therefore, activation of telomerase expression appears to
play an important role during carcinogenesis.
Thyroid neoplasm is the most common neoplastic disorder
encountered in endocrine clinics. The neoplasm usually occurs
with painless thyroid nodules. These thyroid nodules are quite
common in the general population (Vander et al, 1968; Ezzat et al,
1994), yet clinical thyroid cancer develops only in a small fraction
of the population (Mazzaferi, 1992). Thyroid cancer is, however,
the most lethal endocrine neoplasm, excluding that of ovary, and
accounts for about 1% of all cancer deaths (Robbins et al, 1991).
Among the thyroid malignant neoplasms, the most common types
are papillary and follicular carcinomas (Hrafnkeisson et al, 1988;
Lin et al, 1996). At present, little is known about the malignant
progression in thyroid cancers. Mutations in ras and p53 genes
were detected during the progression of normal thyroid tissues to
follicular carcinoma (Lemoine et al, 1988; Ho et al, 1996). On the
other hand, mutations in Ret and other tyrosine kinase oncogenes
were detected in the development of papillary carcinoma
(Bongarzone et al, 1989; Santoro et al, 1992). These results
suggest that oncogenesis in thyroid tissues is multistep and multi-
route. As yet, little is known about the status oftelomerase activity
in the development ofthyroid cancers.
During the course of preparing this manuscript, two articles
dealing with the telomerase activity in thyroid tumours have
appeared (Haugen et al, 1997; Umbricht et al, 1997). Although
telomerase activity was reported to be absent in follicularcarcinomas
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Table 1 Telomerase activity in human thyroid tissues
Telomerase activity
Pathology Total Positive Negative Positive (%)
Nodular hyperplasia 14 2 12 14
Follicular adenoma 14 4 10 29
Papillary carcinoma 23 12 11 52
Follicular carcinoma 11 10 1 91
Table 2 Clinical data and telomerase activity in thyroid papillary and
follicular carcinomas
Fraction of telomerase-positive tissues
Classification Follicular carcinoma Papillary carcinoma
Stage
I'1l 7/8 8/18
III, IV 3/3 4/5
Tumour size
< 3 cm 2/2 7/13
3-5 cm 7/7 4/8
5 cm 1/2 1/2
Thyroglobulin
<10ngml-' 7/8 3/8
10-100 ng ml-' 0/0 3/5
> 100 ng ml-' 1/1 1/2
NDa 2/2 5/8
Patient Age
< 35 years old 3/3 4/11
36-50 years old 3/3 4/5
> 51 years old 4/5 4/7
aND, not determined
and adenomas by Haugen et al (1997), Umbricht et al (1997)
reported the detection of telomerase activity in 11 of 11 follicular
carcinomas and in 8 of 33 follicular adenomas. The discrepancy
between these two reports is currently unresolved. In this work, we
report our evaluation of telomerase activity in 14 hyperplasia, 14
follicular adenoma, 23 papillary carcinoma and 11 follicular carci-
noma tissues.
MATERIALS AND METHODS
Patients, tissues and cells
Tissue samples were obtained by surgical resection of thyroid
tumours from patients admitted at Chang Gung Memorial Hospital
(Taiwan). Twenty-eight samples of benign thyroid tissues, which
included nodular hyperplasia and follicular adenoma tissues, and
thirty-four samples of malignant thyroid tissues, which included
papillary and follicular carcinomas were collected and examined
in this study. The tissues were washed three times with phosphate-
buffered saline (PBS) and stored in liquid nitrogen until use. The
disease status of all tissues was verified by histopathological
examination. Pathological review was performed for all the
thyroid tissues according to the World Health Organization
(WHO) classification (Hedinger et al, 1989). In this study, tumour
staging was classified as previously described (DeGroot, 1995).
Stage I indicates a tumour with a single or multiple intrathyroidal
foci. Stage II indicates a tumour with regional lymph node metas-
tases. Stage III indicates a thyroid tumour with local cervical inva-
sion or fixed cervical metastases. Stage IV indicates lesions
metastatic outside the neck. HeLa cells, kindly provided by Dr C
Chao, were grown at 37°C, 5% carbon dioxide in Dulbecco's
modified Eagle medium (DMEM) containing 10% fetal bovine
serum and antibiotics (100 U ml-' penicillin, 100 U ml-' strepto-
mycin and 0.25 ,ug ml-' amphotericin B).
Thyroglobulin determination
Serum thyroglobulin (Tg) levels were detected using a Tg kit (CIS
Biointernational, France) according to the manufacturer's instruc-
tion. The detection limit of the Tg kit was 0.5 ng ml-'. Interassay
coefficient of variation was 8% at Tg level of 4.9 ng ml-', 6.9% at
232.2 ng ml-' and 5.1% at 312.9 ng ml-'. Data were presented as
means ± s.d.
Telomerase assay
Telomerase activity of tissue samples was assayed blindly with a
code number and the results were decoded later. Tissue samples
(100 mg) were homogenized in 500 1tl of lysis buffer [1O mM
Tris-HCI, pH 7.5, 1 mm magnesium chloride, 1 mM EGTA, 0.5%
CHAPS (Pharmacia), 10% glycerol, 5 mM mercaptoethanol and
0.1 mM phenylmethylsulphonyl fluoride (PMSF)] in Kontes tubes
with matching pestles rotated at 450 r.p.m. For HeLa cell extracts,
cells were resuspended at 5 x 103 per ,ul of lysis buffer. After
30 min at 4°C, the lysate was centrifuged at 16 000g for 30 min at
4°C. The supernatants of tissue and HeLa cell extracts were trans-
ferred to fresh tubes and used for telomerase activity assay. The
protein concentrations were determined using Coomassie protein
assay reagent (Pierce). Telomerase activity was assayed using
PCR-based TRAP (telomeric repeat amplification protocol) (Kim
et al, 1994). In brief, 0.05-5 gg of extract protein was added to a
50-,ul reaction mixture containing 0.1 tg TS primer (5'-AATC-
CGTCGA-GCAGAGTT-3'), 2 units of Taq DNA polymerase (HT
Biotech), 20 mm Tris-HCl (pH 8.3), 1.5 mm magnesium chloride,
63 mm potassium chloride, 0.005% Tween-20, I mM EGTA,
50 ,UM dNTPs, and 0.1 mg ml' bovine serum albumin (BSA). The
reaction mixtures were incubated at 24°C for 10 min, and 0.1 tg
of CX primer (5'-CCCTTACCCTTACCCTTACCCTAA-3') was
then added to initiate PCR amplification. The condition for PCR
amplification was 30 rounds of 94°C for 30 s, 55°C for 30 s, and
72°C for 1.5 min in a DNA Thermal Cycler (Perkin Elmer Cetus).
RNAase digestion was performed as a control by the addition of
0.5 gg of RNAase A (Sigma) to the reaction mixture. The PCR
products were resolved by electrophoresis on a non-denaturing
12% polyacrylamide gel (PAGE) in a buffer containing 54 mM
Tris-HCI, pH 8.0, 54 mm boric acid, 1.2 mM EDTA. The gel was
stained with SyBr green DNA stain (Molecular Probes), visualized
and photographed by illuminating with 254 nm UV.
RESULTS
The presence of telomerase activity in hyperplastic, benign and
malignant thyroid tissues was determined by the standard TRAP
method using 0.5 gg of extract protein in the reaction mixture.
Typical results are shown in Figure 1. Positive telomerase activity
in an extract is determined by the presence of a six-nucleotide
ladder of TRAP products in PAGE that are sensitive to RNAase A
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Figure 1 Detection of telomerase activity in thyroid tissues. For the TRAP
assay shown in this figure, same amount of protein extracts (0.5 jig) from the
tissues of nodular hyperplasia (HP), adenoma (Ad), papillary carcinoma
(PC), and follicular carcinoma (FC) was used. Cell extract from HeLa cells
was served as positive control, and omission of cell extract (B) was served
as negative control
treatment. Tissue samples that did not display telomerase activity
were further confirmed by repeating the TRAP assay using
0.05 gg and 5 g.g of extract protein in the reaction mixtures. In
addition, the presence of inhibitors in the extract was ruled out as
mixing the telomerase-negative extract with that of HeLa cell
extract did not inhibit the telomerase activity (data not shown). A
tally of these results from 14 nodular hyperplasias, 14 follicular
adenomas, 23 papillary carcinomas and 11I follicular carcinomas is
shown in Table 1. Telomerase activity was detectable in 2 of 14
nodular hyperplasias (14%), 4 of 14 adenomas (29%), 12 of 23
papillary carcinomas (52%) and 10 of 11I follicular carcinomas
(91%). The frequency of telomerase-positive tissues in papillary
carcinoma was considerably less than that of follicular carcinoma.
To understand the basis for the absence oftelomerase activity in the
carcinoma tissues, we examined whether the absence oftelomerase
activity may be correlated with tumour stage, tumour size, level of
thyroglobulin or patient age. As shown in Table 2, no significant
correlation was found between the presence of telomerase activity
with tumour size, patient age or thyroglobulin level. The only
follicular carcinoma tissue that was negative for telomerase
activity had a thyroglobulin level of < 10 ng ml-' and was at stage
I. In the case ofpapillary carcinomas, four out offive carcinomas at
stage III or IV were found to be telomerase positive, and 8 out of
18 carcinomas at stage I or II were telomerase positive (Table 2).
DISCUSSION
In this work, we have analysed telomerase activity in thyroid
tissues derived from nodular hyperplasia, follicular adenoma,
papillary carcinoma and follicular carcinoma. Positive telomerase
activity was detected in 2 of 14 nodular hyperplasias (14%), 4 of
14 follicular adenomas (29%) and 10 of 11 follicular carcinomas
(91 %). These results, which are in general agreement with that
reported by Umbricht et al (1997), suggest that telomerase reacti-
vation plays a role in the follicular carcinogenesis. In the case of
papillary carcinoma, positive telomerase activity was detected in
12o 3cacnms 5%.Evlain fciicldt rvae
thtms ftetlmrs-eaietsuso ailr acnm
were at stage I or 11(10/18), whereas only one out of five carci-
nomas at stage III or IV was found to be telomerase negative
(Table 2), suggesting that telomerase reactivation also plays a role
in the papillary carcinogenesis. Haugen et al (1997) reported the
detection of telomerase activity in 10 of 14 papillary carcinomas
(71%). In their analysis for the correlation between tumour inva-
siveness and telomerase activity, they observed that six out of
seven invasive papillary carcinomas had telomerase activity,
whereas only three out ofseven non-invasive papillary carcinomas
had telomerase activity. Therefore, it appears that a significant
fraction of papillary carcinomas at earlier stages is negative for
telomerase activity. The smaller percentage oftelomerase-positive
papillary carcinomas observed in this study may be accounted for
by the many carcinoma samples at earlier stages, i.e. 18 out of 23
samples.
In the malignant thyroid cancers examined in this study, we
observed that the frequency of telomerase-positive tissues in
follicular carcinoma (91%) is higher than that of papillary carci-
noma (52%). The prognosis ofpatients with papillary carcinoma is
generally more favourable than patients with follicular carcinoma.
It is not known whether the prognosis of malignant thyroid disor-
ders may be correlated with the presence of telomerase activity.
Prospective observations are being continued in the patients with
papillary carcinoma to evaluate whether telomerase activity is
correlated with cancer prognosis. In addition, prospective studies
are also being conducted in the patients with benign and hyper-
plasia disorders to investigate whether the presence of telomerase
activity in these non-cancer patients may be correlated with further
cancer development.
In summary, our results reveal that telomerase activity is
detected in the majority ofthyroid cancer at advanced stages (stage
III or IV), frequently in papillary carcinoma at early stages (stage I
or II) and less frequently in benign and hyperplastic tissues. These
results suggest that telomerase reactivation plays a role during
thyroid cancer development. Although the biological significance
oftelomerase activity in non-cancerous thyroid tissue is unclear at
present, it is possible that this enzyme may serve as an early indi-
cation ofthyroid cancer development.
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